A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Day Dose Study to Assess the Safety and Tolerability of JNJ-67670187 in Healthy Participants
Latest Information Update: 07 Jul 2021
At a glance
- Drugs VE 202 (Primary) ; Antibacterials; Laxatives
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 30 Jun 2021 According to a PureTech Health media release, data were presented at the International Human Microbiome Consortium Congress 2021.
- 30 Jun 2021 Results presented in a PureTech Health Media Release.
- 29 Jun 2021 Results published in the Vedanta Biosciences Media Release